Skip to main content

Arena Pharmaceuticals Value Stock - Dividend - Research Selection

Arena Pharmaceuticals

ISIN: US0400476075, WKN: A2DR4A

Market price date: 28.05.2021
Market price: 61,11 USD




Arena Pharmaceuticals Fundamental data and company key figures of the share

Annual reports in USD
Key figures 28-02-2021
Cash flow
Net operating cash flow -353.094.000
Capital Expenditures -820.000
Free cash flow -353.913.984
Balance sheet
Total Equity 1.080.470.000
Liabilities & Shareholders equity 1.190.720.000
Income statement
Net income -404.734.000
Eps (diluted) -6,905
Diluted shares outstanding 58.611.200
Net sales/revenue 319.000

Fundamental ratios calculated on: 28-05-2021

Ratios
Key figures 28-05-2021
Cash flow
P/C -10,14
   
P/FC -10,12
Balance sheet
ROI-33,99
ROE90,74
Income statement
P/E-8,85
Div. Yield0,00%
P/B3,32
P/S11.228,00


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolARNA
Market Capitalization3.581.730.304,00 USD
Country
IndicesNASDAQ Comp.
Sectors
Raw Data SourceUS GAAP in Millionen USD
Stock Split2017-06-20,1.0000/10.0000; 2017-06-19,1.0000/10.0000
Internetwww.arenapharm.com


Description of the company

Arena Pharmaceuticals, Inc. (Arena) is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors. Its wholly owned subsidiary, Arena Pharmaceuticals GmbH (Arena GmbH), has granted Eisai Inc., rights to commercialize BELVIQ in the United States. The Company´s oral drug candidates include APD811, an agonist of the prostacyclin receptor intended for the treatment of pulmonary arterial hypertension, which is in Phase I; temanogrel, an inverse agonist of the serotonin 2A receptor intended for the treatment of thrombotic diseases, which has completed single- and multiple-ascending dose Phase I trials; APD334, an agonist of the S1P1 receptor intended for the treatment of autoimmune diseases, and APD371, an agonist of the cannabinoid receptor 2 intended for the treatment of pain, which is in preclinical development. In June 2012, the United States Food and Drug Administration approved its internally discovered drug, BELVIQ.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.arenapharm.com